Log in

Relevant bibliographies by topics / Heparinoid / Journal articles

To see the other types of publications on this topic, follow the link: Heparinoid.

Journal articles on the topic 'Heparinoid'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Heparinoid.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Успенская, М. С., М. Г. Ляпина, and Е. С. Майстренко. "A heparinoid from peony roots (Paeonia anomala): effects on polymerization and dissolution of fibrin in thrombosis." ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia», no. 2() (June 8, 2020): 80–84. http://dx.doi.org/10.25557/0031-2991.2020.02.80-84.

Full text

Abstract:

Исследование гепаринов и гепариноидов в качестве антитромботических агентов актуально для физиологии и медицины. Многие растения включают гепариноподобные компоненты (гепариноиды), которые препятствуют тромбообразованию. Цель - установление влияния экстракта из корней пиона «Марьин корень» (Paeonia anomala), содержащего гепариноид, на полимеризацию фибрина при процессах тромбообразования ex vivo и определение возможных механизмов его антитромботического действия. Методика. Исследовано влияние гепариноида из пиона (Paeonia anomala) на процессы растворения фибрина в условиях тромбообразования ex

APA, Harvard, Vancouver, ISO, and other styles

2

Alban, S., and A. Greinacher. "Heparinoide als eine Alternative für die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie." Hämostaseologie 16, no. 01 (January 1996): 41–49. http://dx.doi.org/10.1055/s-0038-1656637.

Full text

Abstract:

ZusammenfassungDie Heparin-induzierte Thrombozytopenie (HIT Typ II) ist eine lebensbedrohliche Komplikation der Heparintherapie. Da betroffene Patienten durch diese immunologische, unerwünschte Wirkung der Heparingabe gefährdet sind, neue throm-boembolische Gefäßverschlüsse zu entwickeln, ist bei hinreichendem klinischen Verdacht die sofortige Umstellung auf ein kompatibles Antikoagulans notwendig. Hierfür kommen, neben rekombinantem Hirudin, verschiedene Heparinoide in Betracht. Die Pathophysiologie der HIT Typ II sowie die Struktur und die anti-koagulatorischen Eigenschaften verschiedener He

APA, Harvard, Vancouver, ISO, and other styles

3

Greinacher, A., I. Michels, V. Kiefel, and C. Mueller-Eckhardt. "A Rapid and Sensitive Test for Diagnosing Heparin-Associated Thrombocytopenia." Thrombosis and Haemostasis 66, no. 06 (1991): 734–36. http://dx.doi.org/10.1055/s-0038-1646493.

Full text

Abstract:

SummaryHeparin-associated thrombocytopenia (HAT) is a severe complication of heparin therapy. Its diagnosis is difficult. Conventional assays employ platelet aggregometry (PAA) and/or 14C-serotonin release (SRA) which are either insensitive (PAA) or require radioactive tracers (SRA). We here describe a newly developed sensitive and rapid assay based on visual evaluation of heparin-induced platelet activation (HIPA) in microtiter wells. Using sera of 34 patients with clinically suspected HAT we found the HIPA assay to be as sensitive as the SRA and superior to PAA. The HIPA assay allows investi

APA, Harvard, Vancouver, ISO, and other styles

4

Ishihara, Masayuki, Shingo Nakamura, Yoko Sato, Tomohiro Takayama, Koichi Fukuda, Masanori Fujita, Kaoru Murakami, and Hidetaka Yokoe. "Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers." Molecules 24, no. 24 (December 17, 2019): 4630. http://dx.doi.org/10.3390/molecules24244630.

Full text

Abstract:

Heparinoid is the generic term that is used for heparin, heparan sulfate (HS), and heparin-like molecules of animal or plant origin and synthetic derivatives of sulfated polysaccharides. Various biological activities of heparin/HS are attributed to their specific interaction and regulation with various heparin-binding cytokines, antithrombin (AT), and extracellular matrix (ECM) biomolecules. Specific domains with distinct saccharide sequences in heparin/HS mediate these interactions are mediated and require different highly sulfated saccharide sequences with different combinations of sulfated

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Heparin/heparinoid." Reactions Weekly &NA;, no. 1405 (June 2012): 20–21. http://dx.doi.org/10.2165/00128415-201214050-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mimura, Wataru, and Manabu Akazawa. "The Association Between Internet Searches and Moisturizer Prescription in Japan: Retrospective Observational Study." JMIR Public Health and Surveillance 5, no. 4 (October 8, 2019): e13212. http://dx.doi.org/10.2196/13212.

Full text

Abstract:

Background Heparinoid is a medication prescribed in Japan for skin diseases, such as atopic dermatitis and dry skin. Heparinoid prescription has increased with instances of internet blogs recommending its use as a cosmetic. Objective This study aimed to examine the prescription trends in moisturizer use and analyze their association with internet searches. Methods We used a claims database to identify pharmacy claims of heparinoid-only prescriptions in Japan. Additionally, we used Google Trends to obtain internet search data for the period between October 1, 2007, and September 31, 2017. To an

APA, Harvard, Vancouver, ISO, and other styles

7

ARGE, E. "Heparinoid and Heparin." Acta Medica Scandinavica 155, no. 6 (April 24, 2009): 469–74. http://dx.doi.org/10.1111/j.0954-6820.1956.tb14396.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Preissner, K. T. "Heparinoids and cellular interactions in the vascular system." Hämostaseologie 16, no. 01 (January 1996): 28–34. http://dx.doi.org/10.1055/s-0038-1656635.

Full text

Abstract:

SummaryHeparin and related polysaccharides have long been used for therapautic intervention in different disease states related to thromboembolic complications. The localization and functional availability of heparin-like components in the body is mostly confined to cell surfaces and extracellular matrix/basement membranes. Their strategic position particularly in the vascular system enables heparinoids linked to various core proteins (designated as heparan sulfate proteoglycans) to interact with a variety of heparin-binding proteins such as apolipoproteins, lipases, proteases and protease inh

APA, Harvard, Vancouver, ISO, and other styles

9

Muhl, Lars, Etty Zwang, Neta Ilan, Yair Herishanu, Varda Deutsch, Elizabeth Naparstek, Israel Vlodavsky, Klaus Preissner, and Ben-Zion Katz. "Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms." Thrombosis and Haemostasis 98, no. 12 (2007): 1193–99. http://dx.doi.org/10.1160/th07-04-0256.

Full text

Abstract:

SummaryA key element for the physiological restriction of blood coagulation at the endothelial cell surface is its non-thrombogenic property, mainly attributed to cell surface heparan sulfate proteoglycans. Heparanase is an endo-β-D-glucuronidase with specific heparan sulfate degrading activity, which is produced and stored in platelets, and is released upon their activation. We examined the effects of heparanase pro-enzyme on coagulation functions, predominantly under physiological conditions. While heparanase pro-enzyme does not directly affect coagulation protein activities, it has profound

APA, Harvard, Vancouver, ISO, and other styles

10

Du, ZhenXing, XueJing Jia, Jing Chen, SiYi Zhou, JianPing Chen, XiaoFei Liu, XiaoHuang Cao, SaiYi Zhong, and PengZhi Hong. "Isolation and Characterization of a Heparin-Like Compound with Potent Anticoagulant and Fibrinolytic Activity from the Clam Coelomactra antiquata." Marine Drugs 18, no. 1 (December 19, 2019): 6. http://dx.doi.org/10.3390/md18010006.

Full text

Abstract:

Heparin from mollusks with unique sulfated glycosaminoglycan exhibits strong anti-thrombotic activities. This study reports on a purified heparinoid from Coelomactra antiquata, which shows potent anticoagulant and fibrinolytic abilities. Its structure was characterized by infrared spectroscopy, high-performance liquid chromatography, and one-dimensional and two-dimensional nuclear magnetic resonance spectroscopy. Its fibrinolytic activity was determined in vitro and in vivo. Its anticoagulant activity was determined by activated partial thromboplastin time (APTT), prothrombin time (PT), and th

APA, Harvard, Vancouver, ISO, and other styles

11

Lyapina, M. G., M. S. Uspenkaya, E. S. Maistrenko, and M. D. Kalugina. "INFLUENCE OF HEPARINOID FROM PAEONIA LACTIFLORA ON HEMOSTATIC SYSTEM WITHIN CONDITIONS OF PRETHROMBOSIS." Pharmacy & Pharmacology 7, no. 4 (September 10, 2019): 208–14. http://dx.doi.org/10.19163/2307-9266-2019-7-4-208-214.

Full text

Abstract:

The search and development of direct and rapid anticoagulants used per os, is an urgent problem in physiological and medical science. A number of plants contain heparin-like components with a positive effect on the hemostatic system, both within normal and in some pathological conditions of the body.The aim of the work was to study the complex effect of fibrin, a heparin-like substance (heparinoid) from the roots of Paeonia lactiflora, on fibrinolytic, anticoagulant systems of the body and polymerization processes, when it is administered per os in animals within normal conditions and when mod

APA, Harvard, Vancouver, ISO, and other styles

12

WESSEL, H. P. "ChemInform Abstract: Heparinoid Mimetics." ChemInform 28, no. 34 (August 3, 2010): no. http://dx.doi.org/10.1002/chin.199734300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ortel, Thomas L., Jon P. Gockerman, Robert M. Califf, Richard L. McCann, Christopher M. O’Connor, Diane M. Metzler, and Charles S. Greenberg. "Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis." Thrombosis and Haemostasis 67, no. 03 (1992): 292–96. http://dx.doi.org/10.1055/s-0038-1648434.

Full text

Abstract:

SummaryProgressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiation of an alternative anticoagulant when indicated. The heparinoid Lomoparan (Org 10172) is a mixture of several nonheparin low molecular weight glycosaminoglycans with proven anticoagulant efficacy that is generally non-reactive with platelets in the presence of plasma from patients with heparin induced thrombocytopenia, whereas standar

APA, Harvard, Vancouver, ISO, and other styles

14

Hoek, J. A., M. T. Nurmohamed, K. J. Hamelynck, R. K. Marti, H. C. Knipscheer, H. ten Cate, H. R. Büller, H. N. Magnani, and J. W. ten Cate. "Prevention of Deep Vein Thrombosis following Total Hip Replacement by Low Molecular Weight Heparinoid." Thrombosis and Haemostasis 67, no. 01 (1992): 028–32. http://dx.doi.org/10.1055/s-0038-1648374.

Full text

Abstract:

SummaryWe assessed the safety and efficacy of the novel low molecular weight heparinoid Lomoparan (Org 10172) for the prevention of deep-vein thrombosis in patients undergoing elective total hip replacement in a randomized, placebo-controlled, double-blind trial in 197 consecutive patients. The heparinoid (750 anti-factor Xa-units, s. c., b.i.d.) was administered to 97 patients and 99 patients received placebo. Study medication was started preoperatively and continued for 10 days. Efficacy was assessed by bilateral phlebography at day 10, postoperatively.The incidence of deep-vein thrombosis w

APA, Harvard, Vancouver, ISO, and other styles

15

Maslennikov, А. V., А. G. Yashchuk, G. Kh Gazizova, and E. F. Berdigulova. "Effectiveness of using heparinoids in patients with endometrial dysfunction and concomitant undifferentiated connective tissue disease." Voprosy ginekologii, akušerstva i perinatologii 19, no. 4 (2020): 50–56. http://dx.doi.org/10.20953/1726-1678-2020-4-50-56.

Full text

Abstract:

Objective. To study the effectiveness of heparinoid sulodexide in complex therapy of patients with endometrial dysfunction and concomitant undifferentiated connective tissue disease (UCTD). Patients and methods. We examined 88 patients with UCTD and endometrial dysfunction (the «thin endometrium» phenomenon). The therapeutic regimen of 41 patients (group 1а) additionally to cyclical therapy with 17-b estradiol and didrogesterone was supplemented by continuous heparinoid sulodexide for 3 menstrual cycles (MC), 20 patients (group 1b) in addition to cyclical therapy received the heparinoid from t

APA, Harvard, Vancouver, ISO, and other styles

16

Huhle, G., L. Piazolo, D. L. Heene, and J. Harenberg. "Klinischer Einsatz von Heparinoiden." Hämostaseologie 16, no. 01 (January 1996): 50–55. http://dx.doi.org/10.1055/s-0038-1656638.

Full text

Abstract:

ZusammenfassungHeparinoide werden seit nahezu 40 Jahren klinisch eingesetzt. Indikationsge-biete beruhen auf der entzündungshemmenden und antithrombotischen Wir-kung. Bei oraler Verabreichung steht die profibrinolytische Wirkung im Vordergrund. Für Dermatansulfat liegen pharmakokinetische Untersuchungen vor, die eine längere Halbwertszeit aufweisen im Vergleich zu Heparinen. Die Wirksamkeit bei der Hämodialyse 1st belegt. Das Heparinoid Org 10172 ist vielfältig unter-sucht. Seine Wirksamkeit in der postoperativen Thromboembolieprophylaxe und zur Thromboembolieprophylaxe bei Patienten mit Schla

APA, Harvard, Vancouver, ISO, and other styles

17

Henny, Ch P., H. ten Cate, S. Surachno, P. Stevens, H. R. Büller, M. den Hartog, and J. W. ten Cate. "The Effectiveness of a Low Molecular Weight Heparinoid in Chronic Intermittent Haemodialysis." Thrombosis and Haemostasis 54, no. 02 (1985): 460–62. http://dx.doi.org/10.1055/s-0038-1657872.

Full text

Abstract:

SummaryA new low molecular weight heparinoid, Org 10172 was compared to heparin in a randomized single blind cross-over study in 55 patients with end-stage renal failure undergoing chronic intermittent haemodialysis. The heparinoid administered as a single pre-dialysis i. v. injection of 34.4 anti-Xa units/kg body weight was compared to standard heparin (loading dose 2,500 IU + continuous infusion of 1,800 IU/hr). Mean anti-Xa plasma levels reached were 0.55 and 0.94 anti-Xa units/ml midway dialysis respectively. All 110 dialysis procedures were successfully performed without clotting or bleed

APA, Harvard, Vancouver, ISO, and other styles

18

Greinacher, A., I. Michels, and C. Mueller-Eckhardt. "Heparin-Associated Thrombocytopenia: The Antibody Is Not Heparin Specific." Thrombosis and Haemostasis 67, no. 05 (1992): 545–49. http://dx.doi.org/10.1055/s-0038-1648491.

Full text

Abstract:

SummaryIn this study the hypothesis was assessed whether heparin-associated thrombocytopenia (HAT) may be caused by an antibody dependent on polysulfated oligosaccharide epitopes, present not only on heparin but also on different polysulfated substances such as dextran sulfate and pentosan polysulfate. We found that the major factor for eliciting platelet activation with sera of HAT type II patients is neither the structure nor the AT III binding capacity of an oligosaccharide, but rather its grade of sulfation. This was shown by in vitro crossreactivity studies with 40 sera of HAT type II pat

APA, Harvard, Vancouver, ISO, and other styles

19

Hajjar, D. P., D. B. Boyd, P. C. Harpel, and R. L. Nachman. "Histidine-rich glycoprotein inhibits the antiproliferative effect of heparin on smooth muscle cells." Journal of Experimental Medicine 165, no. 3 (March 1, 1987): 908–13. http://dx.doi.org/10.1084/jem.165.3.908.

Full text

Abstract:

Histidine-rich glycoprotein (HRGP), an alpha-glycoprotein in human plasma that is also present in platelets and macrophages, binds heparin with high affinity and neutralizes its anticoagulant activity. We now report that HRGP specifically inhibits the antiproliferative effect of heparin on arterial smooth muscle cells while other heparinoid-binding proteins do not influence mitogenesis. The multicellular inflammatory response to endothelial injury characterized, in part, by the influx of platelets and macrophages, may be associated with HRGP release into the arterial microenvironment. This rel

APA, Harvard, Vancouver, ISO, and other styles

20

Kumar, Neeraj, A. Bentolila, and A. Domb. "Structure and Biological Activity of Heparinoid." Mini-Reviews in Medicinal Chemistry 5, no. 5 (May 1, 2005): 441–47. http://dx.doi.org/10.2174/1389557053765538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

TSUJI, Hajime. "Proper use of heparin and heparinoid." Japanese Journal of Thrombosis and Hemostasis 19, no. 2 (2008): 187–90. http://dx.doi.org/10.2491/jjsth.19.187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Stopschinski, Barbara E., Talitha L. Thomas, Sourena Nadji, Eric Darvish, Linfeng Fan, Brandon B. Holmes, Anuja R. Modi, et al. "A synthetic heparinoid blocks Tau aggregate cell uptake and amplification." Journal of Biological Chemistry 295, no. 10 (January 23, 2020): 2974–83. http://dx.doi.org/10.1074/jbc.ra119.010353.

Full text

Abstract:

Tau aggregation underlies neurodegeneration in Alzheimer's disease and related tauopathies. We and others have proposed that transcellular propagation of pathology is mediated by Tau prions, which are ordered protein assemblies that faithfully replicate in vivo and cause specific biological effects. The prion model predicts the release of aggregates from a first-order cell and subsequent uptake into a second-order cell. The assemblies then serve as templates for their own replication, a process termed “seeding.” We have previously observed that heparan sulfate proteoglycans on the cell surface

APA, Harvard, Vancouver, ISO, and other styles

23

Chong, BH, F. Ismail, J. Cade, AS Gallus, S. Gordon, and CN Chesterman. "Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172." Blood 73, no. 6 (May 1, 1989): 1592–96. http://dx.doi.org/10.1182/blood.v73.6.1592.1592.

Full text

Abstract:

Abstract Studies were performed to determine the cross-reaction rate of the heparin-dependent antibody with Org 10172, a new low molecular weight heparinoid, and to investigate the effect of Org 10172 on platelet activation induced by the antibody. The plasmas of 17 patients with thrombocytopenia induced by standard heparin were shown, by platelet aggregation studies, to contain the heparin-dependent antibody. Of these 17 patient plasmas, only three cross-reacted with the heparinoid, producing a cross-reaction rate of 18%. When Org 10172 was added to a reaction mixture containing normal platel

APA, Harvard, Vancouver, ISO, and other styles

24

Chong, BH, F. Ismail, J. Cade, AS Gallus, S. Gordon, and CN Chesterman. "Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172." Blood 73, no. 6 (May 1, 1989): 1592–96. http://dx.doi.org/10.1182/blood.v73.6.1592.bloodjournal7361592.

Full text

Abstract:

Studies were performed to determine the cross-reaction rate of the heparin-dependent antibody with Org 10172, a new low molecular weight heparinoid, and to investigate the effect of Org 10172 on platelet activation induced by the antibody. The plasmas of 17 patients with thrombocytopenia induced by standard heparin were shown, by platelet aggregation studies, to contain the heparin-dependent antibody. Of these 17 patient plasmas, only three cross-reacted with the heparinoid, producing a cross-reaction rate of 18%. When Org 10172 was added to a reaction mixture containing normal platelet-rich p

APA, Harvard, Vancouver, ISO, and other styles

25

Hoek, Jaap A., Ch Pieter Henny, Haye C. Knipscheer, Hugo ten Cate, Michael T. Nurmohamed, and Jan W. ten Cate. "The Effect of Different Anaesthetic Techniques on the Incidence of Thrombosis following Total Hip Replacement." Thrombosis and Haemostasis 65, no. 02 (1991): 122–25. http://dx.doi.org/10.1055/s-0038-1647468.

Full text

Abstract:

SummaryWe performed a retrospective analysis on the influence of three types of anaesthesia on the incidence of deep vein thrombosis (DVT) following total hip replacement (THR) in consecutive patients randomized to either the low molecular weight heparinoid Otg 10172 (97 patients), of placebo (99 patients). Ninety patients were operated under epidural anaesthesia, 77 patients under psoas compartment block with additional inhalation anaesthesia, and 29 patients under general anaesthesia. DVT assessment was performed by bilateral venography between days 8 and 12 postoperatively. The overall inci

APA, Harvard, Vancouver, ISO, and other styles

26

Rele, Shyam M., Suri S. Iyer, Subramanian Baskaran, and Elliot L. Chaikof. "Design and Synthesis of Dimeric Heparinoid Mimetics." Journal of Organic Chemistry 69, no. 26 (December 2004): 9159–70. http://dx.doi.org/10.1021/jo049092r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Korsan-Bengtsen, Kristoffer, Walter Berg, and Gunnar Aspenström. "A Clinical Study of a New Heparinoid." Acta Medica Scandinavica 173, no. 1 (April 24, 2009): 107–14. http://dx.doi.org/10.1111/j.0954-6820.1963.tb16511.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ockelford, Paul A., C. J. Carter, and J. Hirsh. "In vivo activity of a new heparinoid." Pathology 17, no. 1 (1985): 78–81. http://dx.doi.org/10.3109/00313028509063731.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

ITO, Y., Y. IGUCHI, and Y. IMANISHI. "Synthesis and non-thrombogenicity of heparinoid polyurethaneureas." Biomaterials 13, no. 3 (1992): 131–35. http://dx.doi.org/10.1016/0142-9612(92)90060-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Borawski, Jacek, Beata Naumnik, Miroslaw Dubowski, and Michal Mysliwiec. "Full-Length TFPI Release by Heparinoid Sulodexide." Clinical and Applied Thrombosis/Hemostasis 16, no. 4 (July 19, 2010): 485–87. http://dx.doi.org/10.1177/1076029609338048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Alban, Susanne, Roland Kaufmann, Edelgard Lindhoff-Last, Wolf-Henning Boehncke, Ralf J. Ludwig, and Marc Schindewolf. "Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides." Thrombosis and Haemostasis 94, no. 12 (2005): 1265–69. http://dx.doi.org/10.1160/th05-05-0318.

Full text

Abstract:

SummaryEczematous lesions, resulting from type IV sensitizations are well-known and relatively frequent cutaneous adverse effects of s.c. heparin therapy. If anticoagulation is further required intravenous heparin, heparinoids or lepirudin may be used as a substitute. However, these alternatives are not optimal in terms of practicability and/or safety-profiles. As molecular weight of different heparin preparations has repetitively been implied to determine the frequency of sensitization, we hypothesized, that due to its low molecular weight the pentasaccharide fondaparinux may provide a practi

APA, Harvard, Vancouver, ISO, and other styles

32

Newton, Faith, Kimberly Glaser, Jennifer Reeves, Lyndsay Sheperd, and Bappaditya Ray. "Refractory Heparin-Induced Thrombocytopenia in a Patient With Subarachnoid Hemorrhage—A Clinical Conundrum." Neurohospitalist 11, no. 4 (February 15, 2021): 360–64. http://dx.doi.org/10.1177/1941874421995377.

Full text

Abstract:

Heparin induced thrombocytopenia (HIT) often resolves with discontinuation of heparin/ heparinoid products. Severe HIT with platelet counts <20,000/µL and disseminated intravascular coagulation is frequently associated with consumptive coagulopathy and systemic thrombosis. Management of severe HIT in patients who fail to improve on discontinuing heparinoid products and argatroban infusion is not well established. We describe a patient admitted with aneurysmal subarachnoid hemorrhage (SAH) who developed severe autoimmune HIT, failed conventional anticoagulation therapy with argatroban and pr

APA, Harvard, Vancouver, ISO, and other styles

33

Boehncke, Wolf-Henning, Lutz Weber, and Helmut Gall. "Tolerance to intravenous admiration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids." Contact Dermatitis 35, no. 2 (August 1996): 73–75. http://dx.doi.org/10.1111/j.1600-0536.1996.tb02293.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

SCHWARZ, ANKE. "New Aspects of the Treatment of Nephrotic Syndrome." Journal of the American Society of Nephrology 12, suppl 1 (February 2001): S44—S47. http://dx.doi.org/10.1681/asn.v12suppl_1s44.

Full text

Abstract:

Abstract.The nephrotic syndrome, caused by glomerulonephritis, diabetes mellitus, or amyloidosis, is still a therapeutic challenge. Newer therapeutic approaches may be sought in the fields of immunosuppression, nonspecific supportive measures, heparinoid administration, and removal of a supposed glomerular basement membrane toxic factor. In immunosuppression, the newer drugs now used in organ transplantation (cyclosporine, tacrolimus, and mycophenolate mofetil) can also be used in the treatment of glomerulonephritis. In nonspecific supportive treatment, angiotensin II receptor antagonists are

APA, Harvard, Vancouver, ISO, and other styles

35

ten Cate, Hugo, Ch Pieter Henny, Jan W. ten Cate, Harry R. Büller, and Nosjir F. Dabhoiwala. "Randomized Double-Blind, Placebo Controlled Safety Study of a Low Molecular Weight Heparinoid in Patients Undergoing Transurethral Resection of the Prostate." Thrombosis and Haemostasis 57, no. 01 (1987): 092–96. http://dx.doi.org/10.1055/s-0038-1651069.

Full text

Abstract:

SummaryIn preparation for an efficacy study, the effect of the low molecular weight heparinoid Org 10172 on postoperative blood loss was assessed in a randomized double-blind, placebo controlled study in patients undergoing transurethral resection of the prostate (TURP). Org 10172 and placebo were given twice daily as i.v. injection for three postoperative days starting one hour preoperatively. Three doses of Org 10172 (800, 1600, and 2400 anti-Xa units b.d.) were evaluated against placebo in three consecutive patient blocks respectively. Each block consisted of 20 patients, 15 receiving Org 1

APA, Harvard, Vancouver, ISO, and other styles

36

Nielsen, Vance G., and Brian T. Geary. "Hepatoenteric ischemia-reperfusion increases circulating heparinoid activity in rabbits." Journal of Critical Care 15, no. 4 (December 2000): 142–46. http://dx.doi.org/10.1053/jcrc.2000.19230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Koya, Madhusudan P., Murugesan Manoharan, Sandy S. Kim, and Mark S. Soloway. "Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted?" BJU International 96, no. 7 (November 2005): 1019–21. http://dx.doi.org/10.1111/j.1464-410x.2005.05783.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Shimada, Shigeki, Hideto Yamada, Tatsuya Atsumi, Takashi Yamada, Noriaki Sakuragi, and Hisanori Minakami. "Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome." Reproductive Medicine and Biology 9, no. 4 (June 15, 2010): 217–21. http://dx.doi.org/10.1007/s12522-010-0056-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Jackson, Mark R., Christopher A. Danby, and Barbara M. Alving. "Heparinoid Anticoagulation and Topical Fibrin Sealant in Heparin-Induced Thrombocytopenia." Annals of Thoracic Surgery 64, no. 6 (December 1997): 1815–17. http://dx.doi.org/10.1016/s0003-4975(97)01065-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hayama, Koremasa, Yusaku Takano, Jin Tamura, Hachiro Tagami, and Tadashi Terui. "Effectiveness of a heparinoid-containing moisturiser to treat senile xerosis." Australasian Journal of Dermatology 56, no. 1 (October 10, 2014): 36–39. http://dx.doi.org/10.1111/ajd.12179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Massey, E. W., J. Biller, J. N. Davis, H. P. Adams, J. R. Marler, L. B. Goldstein, M. Alberts, and A. Bruno. "Large-dose infusions of heparinoid ORG 10172 in ischemic stroke." Stroke 21, no. 9 (September 1990): 1289–92. http://dx.doi.org/10.1161/01.str.21.9.1289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Herzog, S., W. Rath, and W. Kuhn. "Erfolgreiche Therapie einer heparinassoziierten Thrombozytopenie mit einem niedrig-sulfatierten Heparinoid." Geburtshilfe und Frauenheilkunde 55, no. 03 (March 1995): 164–66. http://dx.doi.org/10.1055/s-2007-1022797.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Vannas, Salme, and Ulf Krause. "A TRIAL WITH A PHYSIOLOGICAL HEPARINOID* IN SOME SCLEROTIC CHORIORETINOPATHIES." Acta Ophthalmologica 39, no. 3 (May 27, 2009): 466–74. http://dx.doi.org/10.1111/j.1755-3768.1961.tb00876.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Wessel, H. P., A. Chucholowski, J. Fingerle, N. Iberg, H. P. Marki, R. Muller, M. Pech, et al. "ChemInform Abstract: From Glycosaminoglycans to Heparinoid Mimetics with Antiproliferative Activity." ChemInform 30, no. 21 (June 15, 2010): no. http://dx.doi.org/10.1002/chin.199921293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kumokawa, Tadao, Kazumasa Hirata, Keiichi Sato, and Satoshi Kano. "Dermal absorption of mucopolysaccharide polysulfate (heparinoid) in human and minipig." Arzneimittelforschung 61, no. 02 (November 28, 2011): 85–91. http://dx.doi.org/10.1055/s-0031-1296172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Scott-Burden, T., and F. R. Bühler. "Regulation of smooth muscle proliferative phenotype by heparinoid-matrix interactions." Trends in Pharmacological Sciences 9, no. 3 (March 1988): 94–98. http://dx.doi.org/10.1016/0165-6147(88)90175-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

ten Cate, H., Ch P. Henny, J. W. ten Cate, H. R. Büller, and N. Dabhoiwala. "Heparinoid ORG 10172 in patients undergoing turp: a safety, study." Thrombosis Research 41 (January 1986): 84. http://dx.doi.org/10.1016/0049-3848(86)91513-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Deryck, Y. L. J. M., R. M. Schepp, R. J. van Krugten, and B. Mochtar. "Heparinoid ORG 10172 anticoagulation for cardiopulmonary bypass : A case report." Journal of Cardiothoracic Anesthesia 4, no. 6 (December 1990): 40. http://dx.doi.org/10.1016/0888-6296(90)90111-r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Utsunomiya, R., H. Okazaki, X. Dai, M. Murakami, K. Masuda, H. Mori, K. Shiraishi, M. Tohyama, and K. Sayama. "449 Novel function of heparinoid as an anti-inflammatory agent." Journal of Investigative Dermatology 137, no. 10 (October 2017): S269. http://dx.doi.org/10.1016/j.jid.2017.07.645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Seto, Stephanie L., Megan E. Barra, Russel J. Roberts, and Rachel P. Rosovsky. "Incidence and Outcomes of Heparin-Induced Thrombocytopenia Associated with a Heparin Shortage at a Large Academic Medical Center." Blood 136, Supplement 1 (November 5, 2020): 10. http://dx.doi.org/10.1182/blood-2020-141282.

Full text

Abstract:

Heparin-induced thrombocytopenia (HIT) is a life-threatening complication associated with significant morbidity and mortality in hospitalized patients. The 2019 African swine fever outbreak in China resulted in a critical national shortage of porcine-derived heparin products in the United States. As a result, our institution implemented a multitude of mitigation strategies to reduce heparin utilization by &gt;80% and optimize safe and effective alternative therapies. The aim of this study was to determine whether this change in clinical practice impacted the incidence of HIT and associated

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!